ISCO agrees to sell Lifeline Cell Technology to ATCC for $25M in cash

International Stem Cell CORP

Purchase price $25M, subject to net working capital, cash, and debt adjustments; closing expected Q3 2026.
Seller must obtain stockholder consent from requisite holders; support agreements already signed for >50% voting power.
Indemnity escrow of $2.5M and adjustment escrow of $100K; post-closing adjustment process with 90-day review.
Transition services agreement to be effective at closing; non-solicitation and non-compete covenants for 5 years post-closing.
LCT develops and sells primary human cells, stem cells, and cell culture media for scientific research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.